Goetz C G, Tanner C M, Gilley D W, Klawans H L
Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612.
Neurology. 1989 Nov;39(11 Suppl 2):63-6; discussion 72-3.
We compared the chronic (2-year) effect of substitution with Sinemet CR with the effect of continued administration of standard Sinemet on motor fluctuations and drug-induced side effects in Parkinson's disease (PD). Twelve patients in each treatment group were pair-matched for age, PD duration, duration of levodopa therapy, dosage of Sinemet, PD disability, and side-effect prevalence at study entry. After 2 years, both groups were more disabled from their PD than at baseline; the disability scores were equivalent for the 2 treatments. The Sinemet CR group had fewer fluctuations and fewer side effects. Compared with the standard Sinemet group, Sinemet CR patients had more "on" time (mean 83% versus 62%, p less than 0.001), and had a lower prevalence of disabling chorea (p less than 0.007), dystonia (p less than 0.003) and sleep disruption (p less than 0.002). Prevalence of hallucinations was equivalent for the 2 groups. These results suggest that Sinemet CR is beneficial in ameliorating and preventing the high frequency of some side effects of standard Sinemet treatment.
我们比较了息宁控释片替代治疗的慢性(2年)效果与持续服用标准息宁对帕金森病(PD)患者运动波动和药物所致副作用的影响。每个治疗组有12例患者,根据年龄、帕金森病病程、左旋多巴治疗时长、息宁剂量、帕金森病残疾程度以及研究入组时的副作用发生率进行配对。2年后,两组患者的帕金森病残疾程度均较基线时加重;两种治疗方法的残疾评分相当。息宁控释片组的波动和副作用较少。与标准息宁组相比,服用息宁控释片的患者“开”期时间更长(平均83% 对62%,p<0.001),致残性舞蹈症(p<0.007)、肌张力障碍(p<0.003)和睡眠障碍(p<0.002)的发生率更低。两组幻觉的发生率相当。这些结果表明,息宁控释片有助于改善和预防标准息宁治疗中某些副作用的高发生率。